The road to approval: a perspective on the role of icosapent ethyl in cardiovascular risk reduction.
Mechanistic insights into cardiovascular protection for omega-3 fatty acids and their bioactive lipid metabolites.
The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
Eicosapentaenoic acid: atheroprotective properties and the reduction of atherosclerotic cardiovascular disease events
Eicosapentaenoic acid inhibits oxidation of very large density lipoproteins (VLDL) in a dose-dependent manner over time as compared to docosahexaenoic acid in vitro [abstract].
Eicosapentaenoic acid inhibits high density lipoprotein (HDL) oxidation in a synergistic manner in combination with atorvastatin in vitro [abstract].
Eicosapentaenoic acid inhibits membrane lipid oxidation in a concentration-dependent manner at pharmacologic doses in vitro
Eicosapentaenoic acid (EPA) inhibits human HDL oxidation in a concentration-dependent manner at a pharmacologic dose in vitro.
Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro.
Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro
Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics
Risk of cardiovascular events in patients with hypertriglyceridemia: a review of real-world evidence
Does High-Dose Fish Oil Reduce Cardiovascular Events Via Triglycerides?
Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial
Reduction in First and Total Ischemic Events with Icosapent Ethyl Across Baseline Triglyceride Tertiles
Elevated triglycerides (≥150 mg/dL) and high triglycerides (200–499 mg/dL) are significant predictors of hospitalization for new-onset kidney disease: a real-world analysis of high-risk statin-treated patients.
The eicosapentaenoic acid:arachidonic acid ratio and its clinical utility in cardiovascular disease.
Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin